FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801892105> ?p ?o ?g. }

• W2801892105 endingPage "20708" @default.
• W2801892105 startingPage "20698" @default.
• W2801892105 abstract "// Eva Lhuissier 1 , Juliette Aury-Landas 1 , Valentine Bouet 2 , Céline Bazille 1, 3 , Yohann Repesse 4, 5 , Thomas Freret 2, 6 , Karim Boumédiene 1 and Catherine Baugé 1 1 Normandie Univ, UNICAEN, BioConnecT, Caen, France 2 Normandie Univ, UNICAEN, INSERM, COMETE, Caen, France 3 CHU de Caen, Service d’Anatomie Pathologie, Caen, France 4 Normandie Univ, UNICAEN, INSERM, EFS, PhIND, Caen, France 5 CHU de Caen, Hématologie biologique, Caen, France 6 Normandie Univ, UNICAEN, CURB-BRP, Caen, France Correspondence to: Catherine Baugé, email: catherine.bauge@unicaen.fr Keywords: cognitive functions; antitumoral drug; epigenetic; toxicity Received: December 27, 2017      Accepted: March 22, 2018      Published: April 17, 2018 ABSTRACT Cancer patients display cognitive impairment due, at least partly, to the treatments. Additionally, chemotherapeutic treatments can lead to organ injury, limiting their use, and are likely to have negative impacts on patients’ quality of life. The aim of this study was to investigate the toxicity of 3-Deazaneplanocin A (DZNep) on several tissues and organs, as well as on cognitive functions. DZNep is an inhibitor of S-adenosylmethionine-dependent methyltransferase (in particular of the histone methyltransferase EZH2) which showed antitumoral functions in preclinical trials but whose effects on behavior and on organs (side effects) are not known. Chronic injections of DZNep were performed intraperitoneally in male NMRI mice (2 mg/kg; i.p.; three times per week) during 8 weeks. A follow-up of body weight was assessed during all experiments. Histological analysis were performed on several organs. EZH2 expression and H3K27me3 were assayed by western-blot. Several behavioral tests were performed during treatment and 2 weeks after. A particular focus was made on spontaneous locomotor activity, cognitive functions (spontaneous alternation and recognition memory), and anxiety- and depression-related behavior. Hematological modifications were also assessed. Chronic DZNep treatment transiently reduced animal growth. It had no effect on most organs but provoked a reversible splenomegaly, and persistent testis reduction and erythropoiesis. DZNep administration did not alter animal behavior. In conclusion, this study is encouraging for the use of DZNep for cancer treatment. Indeed, it has no effect on animal behavior, conferring an advantageous safety, and induces irreversible side effects limited on testis which are unfortunately found in most chemotherapy treatments." @default.
• W2801892105 created "2018-05-17" @default.
• W2801892105 creator A5022819232 @default.
• W2801892105 creator A5045349792 @default.
• W2801892105 creator A5045793384 @default.
• W2801892105 creator A5046805410 @default.
• W2801892105 creator A5055600290 @default.
• W2801892105 creator A5058679231 @default.
• W2801892105 creator A5078150458 @default.
• W2801892105 creator A5081062172 @default.
• W2801892105 date "2018-04-17" @default.
• W2801892105 modified "2023-10-17" @default.
• W2801892105 title "Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice" @default.
• W2801892105 cites W1144202826 @default.
• W2801892105 cites W1426193247 @default.
• W2801892105 cites W1917706778 @default.
• W2801892105 cites W1963721982 @default.
• W2801892105 cites W1969357034 @default.
• W2801892105 cites W1983791607 @default.
• W2801892105 cites W1995769259 @default.
• W2801892105 cites W2010711123 @default.
• W2801892105 cites W2016910859 @default.
• W2801892105 cites W2027962334 @default.
• W2801892105 cites W2037548653 @default.
• W2801892105 cites W2043477626 @default.
• W2801892105 cites W2061812825 @default.
• W2801892105 cites W2068122261 @default.
• W2801892105 cites W2069123922 @default.
• W2801892105 cites W2077610561 @default.
• W2801892105 cites W2090006731 @default.
• W2801892105 cites W2100046750 @default.
• W2801892105 cites W2102153391 @default.
• W2801892105 cites W2113634596 @default.
• W2801892105 cites W2117272632 @default.
• W2801892105 cites W2129356506 @default.
• W2801892105 cites W2146778300 @default.
• W2801892105 cites W2157852717 @default.
• W2801892105 cites W2181420494 @default.
• W2801892105 cites W2567957521 @default.
• W2801892105 cites W2601671520 @default.
• W2801892105 cites W2737276581 @default.
• W2801892105 cites W2737477152 @default.
• W2801892105 cites W2763641190 @default.
• W2801892105 cites W818049784 @default.
• W2801892105 doi "https://doi.org/10.18632/oncotarget.25062" @default.
• W2801892105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5945538" @default.
• W2801892105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29755682" @default.
• W2801892105 hasPublicationYear "2018" @default.
• W2801892105 type Work @default.
• W2801892105 sameAs 2801892105 @default.
• W2801892105 citedByCount "9" @default.
• W2801892105 countsByYear W28018921052019 @default.
• W2801892105 countsByYear W28018921052021 @default.
• W2801892105 countsByYear W28018921052022 @default.
• W2801892105 countsByYear W28018921052023 @default.
• W2801892105 crossrefType "journal-article" @default.
• W2801892105 hasAuthorship W2801892105A5022819232 @default.
• W2801892105 hasAuthorship W2801892105A5045349792 @default.
• W2801892105 hasAuthorship W2801892105A5045793384 @default.
• W2801892105 hasAuthorship W2801892105A5046805410 @default.
• W2801892105 hasAuthorship W2801892105A5055600290 @default.
• W2801892105 hasAuthorship W2801892105A5058679231 @default.
• W2801892105 hasAuthorship W2801892105A5078150458 @default.
• W2801892105 hasAuthorship W2801892105A5081062172 @default.
• W2801892105 hasBestOaLocation W28018921051 @default.
• W2801892105 hasConcept C104317684 @default.
• W2801892105 hasConcept C185592680 @default.
• W2801892105 hasConcept C33288867 @default.
• W2801892105 hasConcept C55493867 @default.
• W2801892105 hasConcept C71924100 @default.
• W2801892105 hasConcept C91965660 @default.
• W2801892105 hasConceptScore W2801892105C104317684 @default.
• W2801892105 hasConceptScore W2801892105C185592680 @default.
• W2801892105 hasConceptScore W2801892105C33288867 @default.
• W2801892105 hasConceptScore W2801892105C55493867 @default.
• W2801892105 hasConceptScore W2801892105C71924100 @default.
• W2801892105 hasConceptScore W2801892105C91965660 @default.
• W2801892105 hasIssue "29" @default.
• W2801892105 hasLocation W28018921051 @default.
• W2801892105 hasLocation W28018921052 @default.
• W2801892105 hasLocation W28018921053 @default.
• W2801892105 hasLocation W28018921054 @default.
• W2801892105 hasLocation W28018921055 @default.
• W2801892105 hasLocation W28018921056 @default.
• W2801892105 hasLocation W28018921057 @default.
• W2801892105 hasOpenAccess W2801892105 @default.
• W2801892105 hasPrimaryLocation W28018921051 @default.
• W2801892105 hasRelatedWork W1506200166 @default.
• W2801892105 hasRelatedWork W1995515455 @default.
• W2801892105 hasRelatedWork W2048182022 @default.
• W2801892105 hasRelatedWork W2080531066 @default.
• W2801892105 hasRelatedWork W2604872355 @default.
• W2801892105 hasRelatedWork W2748952813 @default.
• W2801892105 hasRelatedWork W2899084033 @default.
• W2801892105 hasRelatedWork W3031052312 @default.
• W2801892105 hasRelatedWork W3032375762 @default.
• W2801892105 hasRelatedWork W3108674512 @default.
• W2801892105 hasVolume "9" @default.

• next